Andrew Spencer completed his medical training in clinical and laboratory haematology in 1992. He was awarded a LRF (UK) Fellowship and spent 3 years at The Royal Postgraduate Medical School, London, where he undertook research into Bcell clonality in chronic myeloid Leukaemia under the supervision of Professors John Goldman and Junia Melo and was awarded a Doctorate of Medicine from the University of London. Andrew moved to The Alfred Hospital in 1999 where he established an independent translational research program. He established a first-in-human and early phase haematology clinical research unit at The Alfred and was appointed Head of the Malignant Haematology & Stem Cell Transplantation Services in 2007. Andrew has secured research funding of more than 12 million via funding bodies, industry collaborations and philanthropy. He has >100 peer reviewed publications with citations in excess of 3500. Andrew serves on the scientific advisory boards of the International Myeloma Foundation, International Myeloma Working Group and the European Myeloma Network. He is a Director of the Australasian Leukaemia & Lymphoma Group, and the International Myeloma Society. He is the immediate past President of the Haematology Society of Australia & New Zealand.